{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"12.3","value":"7.2"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"12.0","value":"4.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"A durable responder was a responder (i.e. confirmed best tumor response on study of CR or PR) with duration of response of 180 days or more.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"NUMBER","populationDescription":"The secondary efficacy analysis (DRR) was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause.","title":"Durable Response Rate (DRR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}